Figure 1.
Outcomes of MD Anderson cohort in comparison to ALFA-1200 cohort. (A) Comparison of odds ratios between ALFA-1200 and MDACC models. Classifications by cytogenetic risks, odds ratios, and P values were calculated in multivariable Cox models. The OS-fitting model was constructed on the data sets from the ALFA-1200 study group and MDACC. Error bars indicate 95% confidence intervals. (B) OncoPrint plot of relevant factors among all patients (n = 130). Mutations detected by the ALFA-1200 model, status of 3-tier grouping, CBF, and cytogenetic risks were included. (C-D). OS curves of 3-tier grouping for all patients (n = 130) and patients without CBF (n = 93). Kaplan-Meier analysis and pairwise log-rank test were conducted, and P values were adjusted by the Benjamini-Hochberg method in multiple comparisons.

Outcomes of MD Anderson cohort in comparison to ALFA-1200 cohort. (A) Comparison of odds ratios between ALFA-1200 and MDACC models. Classifications by cytogenetic risks, odds ratios, and P values were calculated in multivariable Cox models. The OS-fitting model was constructed on the data sets from the ALFA-1200 study group and MDACC. Error bars indicate 95% confidence intervals. (B) OncoPrint plot of relevant factors among all patients (n = 130). Mutations detected by the ALFA-1200 model, status of 3-tier grouping, CBF, and cytogenetic risks were included. (C-D). OS curves of 3-tier grouping for all patients (n = 130) and patients without CBF (n = 93). Kaplan-Meier analysis and pairwise log-rank test were conducted, and P values were adjusted by the Benjamini-Hochberg method in multiple comparisons.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal